Adverum Director Receives $24K Stock Options Package in Annual Grant

Form 4 filing reveals that Dawn Svoronos, Director at Adverum Biotechnologies (ADVM), was granted stock options on June 17, 2025.

Rhea-AI Filing Summary

Form 4 filing reveals that Dawn Svoronos, Director at Adverum Biotechnologies (ADVM), was granted stock options on June 17, 2025. Key details of the transaction:

• Received 10,450 stock options to purchase common stock
• Exercise price set at $2.32 per share
• Options will vest on the earlier of June 17, 2026 or the 2026 annual stockholders meeting
• Options expire on June 16, 2035
• Vesting is subject to continued service and includes accelerated vesting provision upon change of control

This grant appears to be part of the company's director compensation program. The transaction was reported through an attorney-in-fact on June 20, 2025, within the required SEC filing window.

Insider Trade Summary

Grant/Award: 10,450 shares

Grant/Award 1 txn

Insider Svoronos Dawn

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,450	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 10,450 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest and become exercisable on the earlier of June 17, 2026 or the 2026 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options were granted to Dawn Svoronos at ADVM on June 17, 2025?

Dawn Svoronos was granted 10,450 stock options with an exercise price of $2.32 per share. These options represent the right to buy ADVM common stock and were granted on June 17, 2025.

When do Dawn Svoronos's ADVM stock options vest?

The stock options will vest and become exercisable on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders, subject to continued service. The options include accelerated vesting provisions in the event of a change of control.

What is the expiration date for Dawn Svoronos's ADVM stock options?

The stock options expire on June 16, 2035, which is 10 years from the grant date.

What is Dawn Svoronos's role at ADVM according to the Form 4?

According to the Form 4 filing, Dawn Svoronos serves as a Director of Adverum Biotechnologies, Inc. (ADVM).

What was the total value of stock options granted to Dawn Svoronos in this ADVM Form 4?

The Form 4 shows that Dawn Svoronos received 10,450 stock options with a strike price of $2.32 per share. The filing indicates these options were granted at $0 cost to the director, as they are part of director compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/20/2025 - 04:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Svoronos Dawn

(Last) (First) (Middle)

C/O ADVERUM BIOTECHNOLOGIES, INC.

100 CARDINAL WAY

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adverum Biotechnologies, Inc. [ ADVM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.32	06/17/2025		A		10,450		(1)	06/16/2035	Common Stock	10,450	$0	10,450	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable on the earlier of June 17, 2026 or the 2026 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.

	/s/ Aneta Fergson, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.